The risk of radiation-associated second cancer in patients with cervical cancer following radiotherapy from 1975 to 2019
The Oncologist · 2025
DOI: 10.1093/oncolo/oyaf334 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Shanshan Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, C…. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Neoplasms, Second Primary, Neoplasms, Radiation-Induced. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Shanghai Municipal Science and Technology Commission's Science and Technology Project, The Shanghai Municipal Science and Technology Commission’s Science and Technology Project.
Abstract (Originalsprache)
Background
Radiation-associated second primary malignancies (SPMs) are a significant risk factor affecting the quality of life in long-term cervical cancer survivors. However, the impact of brachytherapy-boost and advanced radiotherapy techniques on the risk of radiation-related SPMs remains unclear.
Methods
We utilized data from the Surveillance, Epidemiology, and End Results (SEER) database (1975-2019) to assess the risk of radiation-associated SPMs among cervical cancer patients. Radiation-associated second solid and hematologic malignancies were defined as those diagnosed in survivors living for ≥5 and ≥2 years, respectively. The fine-gray sub-distribution hazard model was employed to compare the risk of SPMs across different groups.
Results
External beam radiation therapy (EBRT) was associated with an increased risk of pelvic SPMs (sub-distribution hazard ratio [sHR] = 2.13; P < .001). However, no increased risk was observed for extra-pelvic or hematologic SPMs. For radiotherapy-treated patients, the 15-year cumulative incidence of overall pelvic SPMs significantly declined from 3.92% in 1975-1994 to 2.85% in 1995-2006 (sHR = 0.87; P = .036), further decreasing to 2.27% after 2001 compared to those treated in 1975-2001 (sHR = 0.59; P = .030). Brachytherapy alone increased the risk of pelvic SPMs (sHR = 3.04; P < .001), but the combination of brachytherapy with EBRT did not further elevate the risk of pelvic SPMs (sHR = 1.35; P = .092).
Conclusions
The risk of radiation-associated pelvic SPMs has diminished over the past 40 years, and the combination of brachytherapy with EBRT did not further increase the risk of SPMs among cervical cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200233, China.
- Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai 200011, China.
ORCID-Profile: Jie Fu
Förderung
- The Shanghai Municipal Science and Technology Commission's Science and Technology Project
- The Shanghai Municipal Science and Technology Commission’s Science and Technology Project
Zitieren
APA
Wang, S., Yang, X., Gao, Z., Zhao, M., Li, Z., Lu, Y., Jiang, H., Hua, K., & Fu, J. (2025). The risk of radiation-associated second cancer in patients with cervical cancer following radiotherapy from 1975 to 2019. The Oncologist. https://doi.org/10.1093/oncolo/oyaf334
Vancouver
Wang S, Yang X, Gao Z, Zhao M, Li Z, Lu Y, et al. The risk of radiation-associated second cancer in patients with cervical cancer following radiotherapy from 1975 to 2019. The Oncologist. 2025. doi:10.1093/oncolo/oyaf334
BibTeX
@article{Wang2025,
author = {Wang, Shanshan and Yang, Xiaojing and Gao, Zhongrong and Zhao, Mengli and Li, Zhen and Lu, Yuan and Jiang, Hua and Hua, Keqin and Fu, Jie},
title = {The risk of radiation-associated second cancer in patients with cervical cancer following radiotherapy from 1975 to 2019},
journal = {The Oncologist},
year = {2025},
doi = {10.1093/oncolo/oyaf334}
}
EUVIMED